Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Aug;52(2):205-9.
doi: 10.1046/j.0306-5251.2001.01435.x.

Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers

Affiliations
Clinical Trial

Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers

S A Calafatti et al. Br J Clin Pharmacol. 2001 Aug.

Abstract

Aims: The administration of omeprazole may interfere with the absorption of orally administered drugs by reducing gastric pH and hence tablet dissolution. The aim of this study was to investigate the effects of a 5 day administration of omeprazole on the pharmacokinetics of furazolidone.

Methods: Eighteen healthy (nine male and nine female) volunteers were selected. The study had an open randomized two-period crossover design with a 21 day washout period between the phases. Serum concentrations of furazolidone were measured by reversed-phase h.p.l.c. with ultraviolet detection.

Results: Administration of omeprazole caused a significant reduction of Cmax [0.34 microg x ml(-1) (range 0.25-0.43) vs 0.24 microg x ml(-1) (range 0.15-0.34)] with no significant delay in absorption tmax [2.5 h (range 1.85-3.0) vs 2.4 h (range 2.06-2.71)].

Conclusions: Furazolidone was rapidly absorbed after oral administration. Short-term treatment with omeprazole did alter the relative bioavailability of this drug, probably through an effect on absorption kinetics or first-pass metabolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum furazolidone vs time curves (mean ± s.e.mean) obtained in serum of healthy volunteers after the oral administration of 200 mg of furazolidone in the presence (•), and absence of omeprazole (○).

References

    1. American Digestive Health Foundation. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology. 1997;113:S4–S8. - PubMed
    1. NIH Consensus Conference NIH. Consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65–69. - PubMed
    1. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol. 1997;43:223–243. - PMC - PubMed
    1. Lambert JL. Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy. Gastroenterology. 1996;111:521–523. - PubMed
    1. Go MF, Vakil N. Helicobacter pylori infection. Clin Perspectives Gastroenterology. 1999;2:141–153.

Publication types

MeSH terms